Tesla Motors Inc (TSLA), Netflix, ACADIA Pharmaceuticals: This Hedge Fund Manager’s Top Stock Picks for 2017

Kramer also expects Netflix, Inc. (NASDAQ:NFLX) to register growth next year, due to the company continuing to build its international footprint. With the company launching in the majority of countries earlier this year, in 2017 Netflix should further expand its international subscriber numbers, which amounted to 36.8 million at the end of September, up by 95% on the year. Moreover, Kramer pointed out the recent deal between Netflix and Comcast, under the terms of which Netflix, Inc. (NASDAQ:NFLX)’s content became available on Comcast’s set-top box, which provides more access to customers. The company may also enter into similar deals with other cable providers, which can be another catalyst for its stock in 2017. At the end of the third quarter, 55 funds in our database amassed around 9.50% of Netflix, Inc. (NASDAQ:NFLX)’s outstanding stock.

Finally, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of Kramer’s “carry-over” stocks from the last year. The investor pointed out that the company had some positive developments last year, such as the approval of Nuplazid (pimavanserin) for Parkinson’s Disease Psychosis by the FDA, the subsequent strong sales registered by the drug. However, the company’s stock didn’t manage to take off due to issues registered across the entire biotech sector and investors’ disappointment in the company. In his comments sent to us, Kramer considers that Nuplazid sales should continue growing in 2017 and the company is likely to file for the drug’s approval in Europe as well. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)  has recently announced that it will launch new trials for pimavanserin involving Alzheimer’s agitation, adjunctive treatment for  schizophrenia and other therapies. It’s worth mentioning that Acadia’s stock is trading higher today on the back of the company announcing that a Phase 2 exploratory clinical trial of pimavanserin for the treatment of Alzheimer’s disease psychosis met its primary endpoint and showed a statistically significant reduction in psychosis compared to placebo. During the third quarter, the number of funds tracked by us long ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) jumped by three to 28 funds that held roughly 26.80% of the company’s stock at the end of September.

You can watch the video here:

Disclosure: none